QL1706 and Chemo for SMARCA4-deficient lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new immunotherapy drug (QL1706) combined with standard chemotherapy for people with advanced lung cancer that has a specific genetic change (loss of the SMARCA4 gene). The goal is to see if this combination works better than chemo alone.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with advanced (Stage IIIB or IV) non-small cell lung cancer that cannot be removed with surgery or treated with radiation.
- Your tumor has lost the BRG1 protein (a change in the SMARCA4 gene), confirmed by a lab test.
- You have not received any chemotherapy or other cancer treatment for your advanced lung cancer before.
- You are in good enough health to be up and about (ECOG performance status 0 or 1).
- You have at least one tumor that can be measured on a scan.
- Your blood tests show adequate organ function (kidney, liver, bone marrow).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining anlotinib (a targeted drug that blocks tumor blood vessels) with standard chemotherapy for a rare type of advanced lung cancer that lacks the SMARCA4 gene. The goal is to see if this combination helps people who haven't had treatment before.
This trial tests a new drug, LY4050784, for people with advanced solid tumors that have a specific change in a gene called SMARCA4 (BRG1). The study aims to see if the drug is safe and effective. It may be an option for those who have tried other treatments or have no standard options left.
This trial tests a new drug called QL1706 combined with chemotherapy for people with non-small cell lung cancer that has spread or come back after previous treatment with an immunotherapy drug (PD-1/PD-L1 inhibitor) plus chemotherapy. The goal is to see if this combination can help shrink or control the cancer.
This trial tests a combination of four drugs (ABCP) as the first treatment for people with advanced non-squamous lung cancer that has a specific gene change called SMARCA4. The goal is to see if this therapy is safe and works well.
This trial tests a new immunotherapy drug (QL1706) combined with chemotherapy and a type of high-dose radiation therapy called Quad Shot for people with advanced lung cancer that has no known gene mutations. The goal is to see if this combination helps shrink tumors and improve outcomes.
This trial studies whether a study drug called QL1706 added to standard platinum chemotherapy can lower the chance of lung cancer coming back after surgery. It targets people with stage II to IIIB non-small cell lung cancer who have had their tumor fully removed.
Hear when a new SMARCA4-Deficient Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.